ArticleInternational journal of surgery (London, England)2026
Multi-omics analysis identifies TBCB as a therapeutic target in sepsis-induced liver injury.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to identify potential therapeutic targets for sepsis and elucidate the underlying molecular mechanisms, with a particular focus on the liver as a key target organ for experimental validation.
methodsHere, two sequential studies were conducted to uncover and characterize therapeutic targets involved in sepsis-induced liver injury. In Study 1, a proteome-wide Mendelian randomization (MR) analysis was performed using protein quantitative trait loci from deCODE (n = 35 559 Icelanders), UK Biobank (n = 54 219), ARIC (n = 7213 European Americans; n = 1871 African Americans), AGES-Reykjavik (n = 5368 Icelanders), and Fenland (n = 10 708 European ancestry). These datasets were integrated with a sepsis genome-wide association study (GWAS) (FinnGen R12; n = 17 133 cases and 439 048 controls) to identify causal protein candidates. Subsequently, summary-data-based MR was performed. The analysis was based on data from eQTLGen (n = 31 684), GTEx v8 (n = 838 donors), and sepsis GWAS (FinnGen R12; UK Biobank, n = 11 643 cases/474 841 controls). Its goal was to prioritize genes concordant with protein signals. Expression of the candidate was then validated in vivo and in vitro. In Study 2, a metabolite GWAS (n = 8299) was used to investigate metabolic mediation and perform pathway enrichment analysis. Finally, potential small-molecule therapeutics predicted to modulate the prioritized target were identified.
resultsIntegrated multi-omics analyses identified tubulin-folding cofactor B (TBCB) as a promising therapeutic target for sepsis. Quantitative analyses in both in vivo and in vitro models consistently demonstrated significant upregulation of TBCB during sepsis-induced liver injury. Functional knockdown of TBCB significantly attenuated inflammatory signaling. Mechanistically, TBCB appears to contribute to sepsis progression by modulating intracellular lipid metabolism and metabolic homeostasis. Furthermore, molecular docking and dynamics simulations predicted several small molecules for TBCB, suggesting potential therapeutic value.
conclusionThis study identifies TBCB as a central regulator of sepsis pathogenesis, especially in sepsis-induced liver injury. These findings provide novel mechanistic insights and a promising therapeutic target for intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.